Evidence map›Paper›PMID 31929584›Full record

Trial reportPloS one2020

Seroepidemiological study of rubella in Vojvodina, Serbia: 24 years after the introduction of the MMR vaccine in the national immunization programme.

Aleksandra Patić, Mirjana Štrbac, Vladimir Petrović, Vesna Milošević, Mioljub Ristić, Ivana Hrnjaković Cvjetković, Snežana Medić

Open access · goldAbstract readClinical TrialComparative Study
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aleksandra PatićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.ORCID 0000-0002-7068-2882
Mirjana ŠtrbacCentre for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia.
Vladimir PetrovićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Vesna MiloševićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Mioljub RistićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.ORCID 0000-0002-6923-189X
Ivana Hrnjaković CvjetkovićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Snežana MedićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
University of Novi Sad · RSInstitute of Public Health of Vojvodina · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although rubella is usually a mild childhood disease, this infection in early pregnancy poses a serious problem due to its teratogenic effect. The goal of interrupted circulation and elimination of rubella virus was achieved in many countries in the world. The aim of this study was to determine the status of rubella immunity in Vojvodina and evaluate Serbia's progress toward this goal. A total of 3404 residual serum samples from patients of all ages (1 to 84 years) were included in the study. Samples were collected between May 2015 and December 2017 in Vojvodina. Rubella IgG antibodies were determined using an indirect chemiluminescent immunoassay. Percentage of participants seropositive for rubella antibodies was 92.9% in the entire sample. The highest number of seronegatives was in the youngest (1 year) age group (44.7%), followed by the group aged 24-49 (6.4%) and 2-11 years (6.2%). The absence of a higher percentage of children with protective anti-rubella antibodies in the group aged 2-11 can be explained by a lower immunization coverage during certain years. Participants in the group aged 24-49 were born during the pre-vaccination period with lower rubella incidence, leading to the conclusion that not all individuals of that age came into a contact with the virus. Comparing levels of anti-rubella IgG antibodies of seropositive males and females of different ages reveals that the immunity after a contact with the virus and a previously acquired infection is stronger than the immunity after the vaccination. Although the incidence rate of rubella in Vojvodina has been low for the last ten years, there is still a risk of an outbreak due to a decrease in immunization coverage. This study shows that the percentage of susceptible individuals is high, especially considering women aged 24-49, and that additional ("catch-up") immunization is required.

Indexed as

Mass VaccinationNational Health ProgramsRubellaAdolescentAdultAge FactorsAntibodies, ViralChildChild, PreschoolFemaleHumansImmunoglobulin GIncidenceInfantMaleMeasles-Mumps-Rubella VaccineAntibodies, ViralImmunoglobulin GMeasles-Mumps-Rubella Vaccine

Identifiers

PMID31929584
PMCPMC6957133
OpenAlexW2999480614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.